Valeo Pharma (VPH) commercializes innovative prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products.
Valeo Pharma enters into LOI with PCPA regarding its two innovative asthma therapies, Enerzair Breezhaler and Atectura Breezhaler https://t.co/38YDM9ctS5
Valeo Pharma announces commercialization of Enerzair Breezhaler and Atectura Breezhaler following product shipments across Canada and initial deployment of national respiratory sales force. https://t.co/JiOECTt1wg
Valeo Pharma becomes leading player in respiratory diseases following transformational agreement for two innovative asthma treatments. https://t.co/WyGfu4wnPY
#valeopharma#novartis#asthma#agreement
Honored to participate in the fight against COVID-19, with “The Hesperidin Coronavirus Study” to be carried out by the Montreal Heart Institute and Ingenew Pharma Institute (“MHI”) to evaluate our product Hesperco™️.
Read more: https://t.co/zvvFrCTKcv
#valeopharma#Covid_19
Excellent news for patients in Quebec with the positive recommendation for inclusion of Redesca™ on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ). Read more: https://t.co/zI3T24iKd7
#RAMQ#reimbursement#inesss#lmwh#heparin#redesca
It is with great pleasure that we announce a major addition to our senior management team. Mr. @FredericFasano is now Valeo’s new President and COO while Steve Saviuk remains CEO and Vice-Chairman of the Board.
Read more: https://t.co/GgZn2cDUq0
#valeopharma#leadership
There is growing evidence and research suggesting that hesperidin may interfere with SARS-CoV-2 infection process and help against Covid-19 viral replication.
Learn more https://t.co/v5JL7GPwjZ.
Press release https://t.co/YX1z5rT9Ma
#hesperidin#covid19research#covid19news
We are extremely pleased to announce the approval from Health Canada for our low molecular weight heparin biosimilar Redesca™. We expect annual peak sales of $30 million with an impact on revenues starting during the first half of 2021. Read more: https://t.co/64A4qhlPdY
#vph
Good news today as we announce the addition of Amikacin to our hospital specialty products portfolio following Health Canada’s approval, plus the start of Ethacrynate Sodium shipments in the United States. Read more: https://t.co/LaVviJhT1W
#vph#amikacin#ethacrynatesodium
We’re happy to share a link to an article from InvestorIntel written by Frederick Kozak on how Valeo Pharma’s innovative natural health-based product lines are carving their niche in specialty pharmaceuticals. https://t.co/5ihWd5bUhB
#valeopharma#vph
We are very pleased to announce we started shipping our online orders for our immune system support Hesperco capsules, with national retail availability commencing at the end of the month. Order now at https://t.co/VRNVfLSDlX
Press release: https://t.co/98moSLaTAJ